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Abstracts
signed patients into one of two mutually exclusive classes,
and (3) offered a benchmark for a comprehensive disease
management strategy for more involved diabetic patients.
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A MANAGED CARE COST ANALYSIS OF THE
TREATMENT OF PSORIASIS
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There is little published on the relative costs of treatments
in psoriasis.
OBJECTIVE: This study was designed to assess patterns
of medication use, costs, and health care resource utiliza-
tion among US managed care psoriasis patients.
METHODS: Members of 4 HMOs were identified using
pharmacy outpatient and hospital claims data for a
1-year period. Patients were selected if they had (l) at
least 2 claims for psoriasis (lCD-9 code 696, 696.1, and!
or 696.8) or (2) 1 claim for psoriasis and 1 claim for a
psoriasis drug or phototherapy. Descriptive data were
collected to determine psoriasis drug and therapy use,
and total and psoriasis-specific costs.
RESULTS: There were 2,868 members with psoriasis
identified. The data showed that 47.4% of the patients
were on monotherapy and 45% of the patients were on
poly therapy, defined as two or more of the psoriasis-spe-
cific drugs or therapies. This coincides with recent market
evaluations of psoriasis therapies. Topical corticosteroids
were used by 82 % of the patients. Claims for photo-
chemotherapy were made by 9% of members. Eighty per-
cent of patients received therapy from a dermatologist.
There were psoriasis-related hospitalizations for 11 % of
the patients. The median costs for psoriasis-related hospi-
talizations/patient were $252-$1,383 (range: $40-$18,933).
Median total psoriasis-related costs/patient were $155-$170
(range: $0-$24,334).
CONCLUSION: High potency topical corticosteroids re-
main the most commonly used medications for psoriasis.
Even though few patients were hospitalized for psoriasis,
the high costs of hospitalization made it one of the cost
drivers of this condition. Phototherapy procedures, office
visits for non-psoriasis-specific diagnoses, and total drug
costs for psoriasis were additional cost drivers of psoria-
sis treatment.
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EPO was approved for the treatment of anemia in renal
dialysis patients in 1989. In 1991, Medicare changed the
way it reimbursed for EPO, and, in response, there was
59
an increase in average EPO dosages from 2,793 units to
3,200 units in the six-month period following the policy
change. This change, while meant to improve apparently
low EPO dosing, may have had the unintended conse-
quence of maintaining some patients at unnecessarily
high hematocrit levels. These patients may experience
problems associated with relatively high hernatocrits.
Thus, while some patients may have received too little
EPO prior to the policy change, now they may be receiv-
ing too much. Another recent change in EPO reimburse-
ment policy indicates this may be the case. After July 1,
1997 Medicare will reimburse EPO based on a 90-day
rolling average hematocrit measurement. If the average is
above 36.5%, Medicare will not pay for the EPO. This
policy implicitly assumes that high hematocrit levels are
directly related to inappropriately high doses of EPO.
OBJECTIVE: The purpose of this study is to examine the
incidence of complications resulting from abnormally
high hematocrits, such as vascular shunt thrombosis,
among patients with End-Stage Renal Disease (ESRD).
METHODS: This study uses data from the United States
Renal Data System (USRDS) and logistic regression to
model the incidence of adverse events as a function of he-
matocrit level while controlling for confounding factors
such as age, gender, ethnicity, weight, comorbidities, facil-
ity characteristics, dialysis modality, and dialysis history.
RESULTS: Preliminary results suggest that the incidence
of VST has increased since 1991.
CONCLUSION: This study provides Medicare with in-
formation concerning the appropriateness of the 36.5%
cutoff and the projected impact of the change in reim-
bursement.
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Large national claims databases are sources of vital infor-
mation concerning health care resource utilization. How-
ever, the comparability of data obtained from such data-
bases has not yet been ascertained.
OBJECTIVE: To compare prevalence rates of low back
disorders obtained from two large national inpatient
claims databases and to study variations in length of stay
and corresponding costs.
METHODS: Data were obtained from two independent
databases with inpatient claims information including
ICD-9 codes for specific diagnoses, demographics, length
of stay (LOS), and payments or charges made. One of the
databases is a 20% national inpatient sample of all com-
munity hospitals in the U.S. (HCUP). The other national
database consists of data gathered for privately insured
population (MarketScan). Claims for specific diagnoses
of low back disorders (ICD-9 codes: 720.0-724.9) for
1994 were obtained. Using age, gender, and diagnosis-
